Gain Therapeutics Inc (NASDAQ: GANX) is a biotechnology company developing small molecule therapeutics to treat diseases through molecular chaperoning, protein stabilization, and protein modulation. The company generates no product revenue and finances operations through equity offerings, including a June 2024 public offering of 7.1 million shares and 1.0 million pre-funded warrants at $1.35 per share that produced $11.0 million in gross proceeds, and a 2024 at-the-market program that provided $3.0 million in net proceeds. Gain Therapeutics has no products approved for commercial sale and directs spending toward preclinical and clinical research across central nervous system disorders, lysosomal storage disorders, metabolic disorders, and oncology. The company has never declared or paid a cash dividend and does not intend to do so. As of the 10-K filed March 26, 2026, the company remains pre-revenue and dependent on external financing to fund operations.

Revenue model

No product revenue as of the fiscal year ended December 31, 2025. Operations are funded through equity offerings and at-the-market programs. The company has not generated substantial product revenue and may seek future collaboration or licensing arrangements.

Products and services

Small molecule drug candidates targeting misfolded proteins via molecular chaperoning, aimed at central nervous system disorders, lysosomal storage disorders, metabolic disorders, and oncology. All programs are in preclinical or clinical development stages as of the 10-K filed March 26, 2026.

Customers and end markets

No commercial customers as of the fiscal year ended December 31, 2025. Target end markets include CNS disorders, lysosomal storage disorders, metabolic disorders, and oncology.

Value-chain role

Drug discovery and development stage company. Outsources research, preclinical, and clinical activities to contract research organizations and universities. Does not manufacture or commercialize products.

Geographic exposure

Headquartered in the United States. Conducts research collaborations with third parties including international partners. Subject to data privacy regulations across the United States, European Economic Area, United Kingdom, and Switzerland.

Source: SEC 10-K, filed 2026-03-26

Industry: Pharmaceutical Preparations Peers: Aligos Therapeutics Inc Applied Molecular Transport Inc. Protara Therapeutics Inc Athenex, Inc. Beyondspring Inc CASI Pharmaceuticals, Inc (DE) PhaseBio Pharmaceuticals Inc Eledon Pharmaceuticals Inc Molecular Templates, Inc.